CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Compare volatility levels for Dividend Aristocrats ETF and apply practical tactics to manage risk and maximize stability.
22,003 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
U.S. stocks drift as a slate of fresh analyst calls prompts traders to reassess positions in consumer, tech and indus...
A wave of data center spending powered by AI is reshaping the investment landscape. This article explains which stock...
As AI infrastructure names retreat from spring highs, June market conditions and resilient AI demand are prompting in...
Oil could move through strait hormuz before fertilizer shipments restart, signaling a rare reopening of the chokepoin...
SpaceX’s IPO buzz is reshaping how traders view tech hardware plays. This story explains why micron stock after space...
Urban air taxis are moving from concept to reality. This article explores Joby Aviation, the eVTOL pioneer, and wheth...
In morning trading, Tesla sinks about 5% while Lucid edges higher and Rivian drifts, signaling a diverging path for t...
A meme-focused token from MemeCore dropped roughly 70%, sending its market cap below $1 billion and triggering renewe...
In 2026, investors face a choice between a reliable components maker and a bold energy storage innovator. This guide ...
Investors are buzzing about a potential shift in how Rocket Lab does business. This article delves into what a SpaceX...
Oklo is developing compact nuclear reactors geared for AI data centers. This article lays out a grounded five-year ro...